Press Releases

February 26, 2014 Lupin Receives FDA Approval for Generic Mycobutin® Capsules

February 18, 2014 Lupin Appoints Dr. Maurice Chagnaud as President-Europe & Head of Inhalation Strategy

February 3, 2014 Strong Growth, Record Profits Quarter III Results, FY 2013-14 Net Sales up 21%; EBITDA up 28%; Net profit up 42% Declares Interim Dividend of 150 %

February 3, 2014 Lupin Receives FDA Approval for Generic Mycobutin® Capsules

December 18, 2013 Lupin launches Generic Trizivir® Tablets

December 12, 2013 Lupin launches Generic Cymbalta® Delayed-Release Capsules 20 mg, 30 mg and 60 mg strengths in the US

December 10, 2013 Lupin Receives FDA Approval for Generic Trizivir® Tablets

December 6, 2013 Lupin launches Generic Trilipix® Delayed-Release Capsules 45 mg & 135 mg in the US

November 11, 2013 Lupin launches Generic Aciphex® Delayed-Release Tablets, 20 mg in the US